carboplatin,durvalumab,paclitaxel,olaparib,bevacizumab
astrazeneca,merck,roche
['olaparib', 'durva', 'duo-o', 'gyn', 'ovarian']
 new! #asco23 study summary for patients: adding #immunotherapy durvalumab and #targetedtherapy olaparib to standard treatment delays growth of advanced #ovariancancer in duo-o clinical trial #gyncsm
Timely, trusted, compassionate doctor-approved info from @ASCO. Signup https://t.co/2KibiNRMFU

We can't answer individual medical questions.

Retweet ≠Endorsement